Kura Oncology (NASDAQ:KURA) Given “Buy” Rating at Cowen

Cowen reiterated their buy rating on shares of Kura Oncology (NASDAQ:KURA) in a report issued on Friday, AnalystRatings.com reports.

KURA has been the topic of a number of other reports. JMP Securities reissued a market outperform rating and issued a $22.00 price objective on shares of Kura Oncology in a report on Thursday, September 5th. BidaskClub raised Kura Oncology from a sell rating to a hold rating in a report on Wednesday, November 27th. ValuEngine upgraded Kura Oncology from a hold rating to a buy rating in a research report on Tuesday. Wedbush reiterated a positive rating on shares of Kura Oncology in a report on Wednesday, September 4th. Finally, Zacks Investment Research downgraded shares of Kura Oncology from a buy rating to a hold rating in a report on Tuesday, November 12th. Two investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The stock presently has a consensus rating of Buy and an average price target of $25.43.

Shares of NASDAQ:KURA traded up $0.40 on Friday, hitting $15.61. 399,861 shares of the company were exchanged, compared to its average volume of 261,419. Kura Oncology has a 1-year low of $12.30 and a 1-year high of $21.42. The stock’s 50 day moving average price is $15.16 and its 200 day moving average price is $16.82. The company has a current ratio of 19.29, a quick ratio of 19.29 and a debt-to-equity ratio of 0.03. The firm has a market capitalization of $707.37 million, a P/E ratio of -9.08 and a beta of 2.56.

Kura Oncology (NASDAQ:KURA) last released its earnings results on Tuesday, November 5th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.03. On average, equities analysts predict that Kura Oncology will post -1.53 EPS for the current fiscal year.

A number of large investors have recently bought and sold shares of KURA. Brown Advisory Inc. acquired a new stake in Kura Oncology during the 2nd quarter worth about $11,799,000. State Street Corp boosted its stake in shares of Kura Oncology by 52.0% in the third quarter. State Street Corp now owns 1,226,528 shares of the company’s stock worth $18,606,000 after buying an additional 419,582 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Kura Oncology by 23.0% in the second quarter. Vanguard Group Inc. now owns 2,012,548 shares of the company’s stock worth $39,628,000 after buying an additional 376,172 shares during the last quarter. Marshall Wace LLP grew its holdings in Kura Oncology by 1,449.5% during the second quarter. Marshall Wace LLP now owns 347,698 shares of the company’s stock worth $6,846,000 after acquiring an additional 325,258 shares during the period. Finally, Citadel Advisors LLC acquired a new stake in Kura Oncology during the second quarter worth about $5,940,000. 88.72% of the stock is currently owned by institutional investors.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.

Recommended Story: What is total return in investing?

Analyst Recommendations for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.